Thomas Björk (Former)
11 – 20 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
(
- Contribution to journal › Article
- 2007
-
Mark
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
(
- Contribution to journal › Article
-
Mark
Prostataspecifikt antigen--den viktigaste cancermarkören. Diagnostik och uppföljning av prostatacancer har förändrats markant.
(
- Contribution to journal › Article
- 2006
-
Mark
Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at -20 {degrees}C.
(
- Contribution to journal › Article
-
Mark
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
(
- Contribution to journal › Article
-
Mark
Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
(
- Contribution to journal › Article
- 2004
-
Mark
Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
(
- Contribution to journal › Article
- 2003
-
Mark
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
(
- Contribution to journal › Article
-
Mark
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
(
- Contribution to journal › Article